JP2007110904A - Functional raw material containing useful phospholipid composition, and functional food - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a functional raw material containing a useful phospholipid composition, wherein useful phospholipid and functional substance work as active ingredients, and their synergic effect is effectively used to improve its physiological activity. <P>SOLUTION: The functional raw material containing a useful phospholipid composition 1 contains a useful phospholipid composition containing omega-3 highly unsaturated fatty acid bonding phospholipid, and functional substance. The functional substance 3 can be included in liposome 2 comprising a useful phospholipid composition. The liposome is generated from the useful phospholipid in water while the functional substance is simultaneously added to obtain useful phospholipid liposome including the physiologically active ingredient of the functional substance to improve systemic absorption efficiency of the functional substance so that even a small amount of the substances results in exerting equal or superior physiological function. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a functional material containing a useful phospholipid composition and a functional food to which the functional material is added. More specifically, a functional material containing a useful phospholipid composition and a functional substance as active ingredients, a functional material containing the functional substance in a liposome formed by the useful phospholipid composition, and the functional material Relates to functional foods.

  In recent years, various functional foods have attracted attention as health consciousness increases. One of them is a useful phospholipid that can be taken from seafood (see Patent Document 1 and Non-Patent Document 1). This is rich in polyunsaturated fatty acid esters such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), which are useful for human health. ing.

  There are various components that constitute various functional substances useful for the human body, but for example, the new oil component is hardly soluble in human body fluids composed of water, blood, etc., so the absorption efficiency into the human body is not necessarily high, Expensive and valuable materials may be wasted. Various formulation techniques for improving the absorption efficiency of these lipophilic components and hydrophilic components have been devised, and have become important elemental technologies in the food and pharmaceutical fields.

  As a material mainly belonging to the category of functional foods, it has been widely used in recent years to improve body modulation (metabolic syndrome, etc.) resulting from disorder of lifestyle habits by ingesting various functional food materials derived from nature. There is something that became. Among these, there are many expensive materials with a small supply amount because it is difficult to obtain raw materials and the production amount is limited. For example, Agaricus (Non-Patent Document 2), Coenzyme Q10 (Non-Patent Document 3), blueberry, lutein, astaxanthin and the like can be mentioned. It is desired to improve the bioavailability of these expensive and valuable functional substances, that is, to achieve the same or better effect in a smaller amount.

Japanese Patent Laid-Open No. 11-123052 JP 2002-272493 A Yoshie Inoue, Food and Development, 31, 1, p. 49 Agaricus Internet <URL: HYPERLINK "http://www.aicplus.com/about" http://www.aicplus.com/about agaricus / index.html, searched on August 19, 2005 Japan Coenzyme Q Association Internet <URL: HYPERLINK "http://www.coenzymeq-jp.com/enterprise.html#q10" http://www.coenzymeq-jp.com/enterprise.html#q10, August 2005 Search on the 19th Fragrance Journal, No. 15, p. 68-76, 1965

  However, there is a problem that functional materials usable for functional foods and preparations that can more efficiently absorb functional substances that are useful and expensive for the human body have not been obtained.

  In view of the above-mentioned problems, the present invention provides a functional material containing a useful phospholipid composition that has a useful phospholipid and a functional substance as active ingredients, and that effectively uses the synergistic function to improve physiological activity. It aims at providing the functional food containing this.

  The present inventors have conducted intensive research and administer a useful phospholipid and a functional substance in combination, or include a useful phospholipid composition in which a functional substance is encapsulated in liposomes of the useful phospholipid. It has been found that a functional material can enhance its physiological function as compared with the case where a functional substance alone is administered, and the present invention has been completed.

In order to achieve the above object, the functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance as active ingredients. It is characterized by.
According to the said structure, the functional raw material containing a useful phospholipid composition with a very high bioactive function can be provided by the synergistic effect of the bioactive function of a phospholipid composition useful for a human body, and a functional substance.

Moreover, the functional material containing the useful phospholipid composition of the present invention comprises a liposome composed of a useful phospholipid composition containing an omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance. It is characterized by being encapsulated in liposomes.
According to this configuration, functional substances useful for the human body are encapsulated in liposomes formed from useful phospholipids with excellent emulsifying properties, and increase bioavailability in the body, thereby improving physiologically active functions. Can do.

In the above configuration, the omega-3 highly unsaturated fatty acid-binding phospholipid is preferably 10% by weight or more, preferably 20% by weight or more of the fatty acid ester-bonded in the phospholipid, with DHA (docosahexaenoic acid) and / or EPA ( Eicosapentaenoic acid).
The omega-3 highly unsaturated fatty acid-binding phospholipid is preferably a useful phospholipid composition in which the omega-3 highly unsaturated fatty acid content is increased by transesterification.
The functional substance is preferably a functional food material. Preferably, the functional substance is a pharmaceutical material. The functional substance is preferably Agaricus or coenzyme Q10.
Preferably, the omega-3 polyunsaturated fatty acid-binding phospholipid is derived from an aquatic product, and the aquatic product is a fish egg, a gonad of a marine animal, a squid, a scallop, a starfish, a seaweed, or a microorganism. is there.

  According to the above configuration, the useful phospholipid is a naturally-derived omega-3 highly unsaturated fatty acid-binding phospholipid, and contains a food material or a pharmaceutical material as a functional substance therein, or these functionalities. A functional material containing a useful phospholipid composition encapsulating a substance can be provided. In particular, when the functional substance is agaricus or coenzyme Q10, the effect is remarkable, and a higher physiologically active function can be expressed than any simple substance of omega-3 highly unsaturated fatty acid-binding phospholipid or agaricus.

The functional food of the present invention is preferably added with a functional material containing the useful phospholipid composition. In this case, the functional food is preferably a beverage.
According to the said structure, the functional food which can take in the functional raw material containing the useful phospholipid composition which encloses a functional substance from solid food, a drink, etc. can be provided.

  ADVANTAGE OF THE INVENTION According to this invention, a functional substance can be included in the liposome which contains a useful phospholipid composition and a functional substance, or consists of a useful phospholipid composition, and can improve the bioavailability. A functional material and a food containing the functional material can be provided. In particular, when it is drunk, the absorption efficiency of the functional substance in the body can be improved.

Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.
First, a functional material containing the useful phospholipid composition of the present invention will be described.
The functional material containing the useful phospholipid composition of the present invention comprises a useful phospholipid composition and a functional substance as active ingredients. In a useful phospholipid composition containing a useful phospholipid as a main component, the phospholipid is, for example, a glycerin phosphate ester represented by the chemical formula (1), and is often found in seafood, egg yolk, soybeans and the like. Included and extracted.
Here, R ₁ COO and R ₂ COO are fatty acid residues, and X is selected from choline (PC), ethanolamine (PE), inositol (PI), serine (PS), and glycerol (PG). Such as an alcohol amine group. The group X may be a group in which a polyhydric alcohol is ester-bonded.

Examples of such glycerin phosphates include phosphatidylcholine represented by chemical formula (2) and phosphatidylserine represented by chemical formula (3).
Here, R ₁ COO and R ₂ COO are fatty acid residues, and X of the glycerol phosphate ester represented by the chemical formula (1) is choline (PC) or serine (PS).

Chemical structural formulas in the case where the fatty acid residue as R ₁ COO is a DHA (docosahexaenoic acid) group or an EPA (eicosapentaenoic acid) group are shown in the following formulas (4) and (5). These DHA and EPA are both called omega (ω) -3 highly unsaturated fatty acids because the carbon located third from the end has an unsaturated bond, and such omega-3 Phospholipids containing polyunsaturated fatty acids are omega-3 polyunsaturated fatty acid binding phospholipids. In the present invention, omega-3 highly unsaturated fatty acid-binding phospholipid is referred to as useful phospholipid, or simply omega-3 binding phospholipid or n-3 phospholipid.

  Useful phospholipids have a structure that has a good balance between the phosphate group as the hydrophilic group and the alkyl group and alkenyl group as the lipophilic group, so it has a surfactant function, and is in water, in human body fluids, in human cells. The liposome which is emulsified fine particles is formed, and the hydrophilic component and the lipophilic component are taken into the liposome.

The chemical substance that forms an ester bond to the phosphate portion of the useful phospholipid is mainly phosphatidylcholine, which is choline. However, by coexisting phosphatidylserine, which is a phospholipid with serine, it can be added to the surface of the liposome. By imparting electric charges, it is possible to electrically repel each other in the liquid and to significantly increase the stability of the liposomes in the dispersion. The coexistence concentration is 5% by weight or more and the stability is remarkable, and 60% by weight or less is preferable. In addition, it is essential that the fatty acid that forms an ester bond in the useful phospholipid contains DHA and / or EPA, which are omega-3 highly unsaturated fatty acids. The effect of the present invention can be obtained if omega-3 highly unsaturated fatty acid is contained even in a small amount, but the higher the concentration, the more effective. Specifically, a clear effect is exhibited at 10% by weight or more of the fatty acid ester-bonded in the useful phospholipid, preferably 20% by weight or more.
Here, phosphatidylserine may be produced by extraction from phospholipids derived from aquatic products, or can be produced by converting phospholipids such as phosphatidylcholine by phosphatidyl group transfer reaction in the presence of L-serine ( Patent Document 2). Moreover, you may extract by transesterification by an enzyme method etc. Furthermore, by adding cholesterol appropriately in the range of 1% by weight to 50% by weight, the strength of the liposome membrane can be increased and the dispersion stability can be enhanced.

  The functional substance 2 may be anything as long as it is a functional food material or a pharmaceutical material. Examples of such functional food materials include mushroom extract such as Agaricus, Meshimakobu, Hanabiratake, carotenoids such as coenzyme Q10, water-soluble peptide, carotene, polyphenol, tea catechin, ginkgo biloba extract, various herbs, isoflavones, etc. Flavonoids, folic acid, vitamins, minerals, amino acids, tocopherol, glucosamine, hyaluronic acid, chondroitin sulfate, collagen, fucoidan, chitin, chitosan, blueberry, lutein, astaxanthin, and omega-3s such as DHA and EPA Examples include fatty acids and conjugated fatty acids (CLA). Among these, Agaricus is known to show a remarkable anticancer effect. In addition, coenzyme Q10 is a substance that is also produced in human cells and is called a “genuine element” of the human body, and many products are sold as adjuvants for health, beauty and physical fitness.

  In general, pharmaceuticals have inconvenient side effects unlike foods. For example, anticancer agents such as adreamycin, cisplatin, and taxol are widely used for the treatment of cancer because they exhibit an excellent cancer killing cell effect. However, when the amount used is increased in order to enhance the effect, side effects such as hair loss and nausea become stronger, which is an obstacle to treatment. When the efficacy of these pharmaceuticals is enhanced by the functional material containing the useful phospholipid composition of the present invention, the amount of the pharmaceuticals used can be reduced and the level of side effects can be greatly reduced. As a result, it is also an excellent effect of the present invention that the quality of life of the patient can be remarkably improved.

According to the functional material containing the useful phospholipid composition of the present invention, a functional food having an extremely high physiological activity function is provided by a synergistic effect of the physiological activity function of the phospholipid composition useful for the human body and the functional substance. be able to.
In particular, when the functional substance is agaricus, the effect is remarkable, and a higher bioactive function can be expressed than either the phospholipid composition or the simple substance of the functional substance.

Next, as yet another functional material of the present invention, a functional material containing a useful phospholipid composition in which a functional substance is encapsulated in liposomes composed of omega-3 linked phospholipid will be described.
FIG. 1 schematically shows the structure of a functional material containing another useful phospholipid composition of the present invention. In the figure, the functional material 1 containing the useful phospholipid composition of the present invention includes a functional substance 3 made of an active ingredient of a functional food material or a pharmaceutical material in a liposome 2 made of useful phospholipid. . In the liposome 2 encapsulating a functional substance, useful phospholipids are emulsified and aggregated in water to form fine particles. The particle diameter of the liposome 2 varies depending on the liposome formation conditions, and is usually 10 μm or less, more preferably 1 μm or less.
Here, as useful phospholipids and functional substances, the same materials as the above functional materials can be suitably used. Furthermore, useful phospholipids may be modified or derivatives of phospholipids to which omega binds and have a liposome effect. Such a lipid may be a glycolipid such as digalactosyl diacylglycerol (DGDG).
In addition, the functional material 1 containing the useful phospholipid composition of the present invention is also referred to as a liposome preparation 1 containing the functional substance 3 or simply a liposome preparation 1 as appropriate.

The liposome is a closed vesicle that forms a bilayer composed of useful phospholipids and has an aqueous phase therein. This is different from a system in which one of two liquids such as water and oil that are not mixed is finely dispersed and dispersed in the other phase, which is emulsification (emulsion). In normal emulsification, the emulsion is stabilized using a surfactant or the like. Although useful phospholipids themselves have a surfactant action, they are used as liposome bilayers in the present invention. As the form of liposomes, multilamellar liposomes (0.1 to several μm) and unilamellar liposomes (0.01 to several μm) are known. The former includes multilamellar liposomes (MLV), multilamellar liposomes (OLV), and multiphase liposomes, and the latter includes small unilamellar liposomes (SUV), large unilamellar liposomes (LUV), and a huge single liposome. There are membrane liposomes (GUV). As long as the required amount of functional substance can be retained in the internal aqueous phase or bilayer membrane phase, any of them may be used, but single membrane liposomes are preferred.
Here, vortexing method, sonication method, reverse-phase evaporation method, etc. can be used as a method for preparing and producing liposomes (see Non-Patent Document 4). The mass production method may be a polyhydric alcohol method, a heating method, a spray drying method, a mechanochemical method, or the like.

  The functional material containing the useful phospholipid composition of the present invention can be produced by encapsulating the functional substance 3 in the liposome during the formation of the liposome composed of the useful phospholipid. In this case, the functional substance is preferably added to the inside of the liposome in an amount of 1 to 90% by weight, preferably 20 to 70% by weight.

According to the functional material containing the useful phospholipid composition of the present invention, as shown in FIG. 1, the liposome 2 is formed with the useful phospholipid and the functional substance 3 is encapsulated therein. A functional material 1 composed of liposomes of useful phospholipids encapsulating a functional substance that improves bioavailability can be provided. Therefore, when used for a functional material containing the useful phospholipid composition of the present invention, it is possible to exert physiological functions more than the administration of the functional substance alone.
In this case, useful phospholipids are known to have many physiological activities, and are also good surfactants. Therefore, the functional material in which the useful phospholipid itself is made into liposomes and the functional material is encapsulated therein can be dispersed without using other additives such as a special surfactant. For this reason, the liposome 2 can be efficiently formed by adding a useful phospholipid to water and applying a treatment to form a lipid bilayer of phospholipid.

  Furthermore, useful phospholipids have physiological activities such as improvement of learning function such as liver function improvement, blood pressure lowering, anti-allergy, memory ability, and anti-cancer, so that the active ingredient of functional substance 3 and useful phospholipids The overall physiological function can also be improved by a synergistic effect with the physiologically active ingredient.

  Here, as a mechanism for improving the physiologically active function, the absorbability in the small intestine is increased, the decomposition of functional substances in the intestine and the body is maintained, the blood concentration is maintained by sustained release, and it is similar to the biological membrane It is thought to be due to the fact that the structure promotes the interaction with cells. In addition, it is presumed that the functional substance can be accumulated at a high concentration in a specific part of the living body (target part of the disease). Furthermore, activation of immune cells of Peyer's patches of the intestinal tract, and liposomes made with omega-3 highly unsaturated fatty acid-binding phospholipids have cancer cell growth inhibitory effects, and omega-3 highly unsaturated fatty acid binding Various factors such as a synergistic effect with other physiological functions of the phospholipid itself or a combined effect thereof can be considered, but details are unknown.

Next, a method for producing a functional material containing a useful phospholipid composition in which the useful phospholipid of the present invention itself is made into a liposome and the functional material is encapsulated therein will be described.
By emulsifying a mixture of a useful phospholipid composition and a predetermined functional substance in water, a liposome preparation encapsulating the functional substance can be prepared. This emulsification can be carried out by vigorously stirring water, the useful phospholipid composition and the functional substance, or by jetting them through micropores. In particular, when the functional substance is hydrophilic, the functional substance is easily taken into the phospholipid bilayer membrane of the liposome to form a uniform emulsion (see FIG. 1). Further, when the functional substance is lipophilic, a part or all of the functional substance is sandwiched between the layers of the phospholipid bilayer inside the liposome and held, that is, encapsulated inside the phospholipid. The particle size of the liposome formed by emulsification is 10 μm or less. The smaller the particle size, the more stable the liposome in an aqueous medium, and the stability is improved when 5% by weight or more of serine is contained as a chemical substance ester-bonded to the phosphate moiety in the useful phospholipid. The particle size distribution can be appropriately adjusted by the method of liposome formation. What is necessary is just to design a particle size and a particle size distribution suitably according to a use.

  Useful phospholipids are extracted and purified from fish eggs such as salmon roe, demolition waste such as bonito and tuna, gonads, squids, starfish, scallops, starfish, seaweeds, microorganisms and other aquatic products. Omega-3 highly unsaturated fatty acid linked phospholipids can be used.

  According to the above production method, the functional material containing the useful phospholipid composition, in which the useful phospholipid itself of the present invention is made into a liposome and the functional material is encapsulated inside or between the phospholipid bilayers, is efficiently produced. can do.

Hereinafter, the present invention will be described in more detail with reference to examples.
As Example 1, a functional material containing a useful phospholipid composition containing a useful phospholipid composition and a functional substance as active ingredients was produced.
Specifically, omega-3 highly unsaturated fatty acid-binding phospholipid derived from squid meal dissolved in hexane is placed in an eggplant-shaped flask so that the phospholipid forms a thin film on the side wall under a nitrogen gas stream. The mixture was dried and further left standing under reduced pressure to completely distill off the solvent to obtain a dried product. 0.4 g of this dried product was dispersed in 1000 cm ³ of pure water. On the other hand, 1 g of a water extract extract freeze-dried powder of Agaricus (manufactured by Health Science Co., Ltd., AICPLUS) was dissolved in 1000 cm ³ of pure water.
Next, the functional dispersion of Example 1 was prepared by mixing equal amounts of the water dispersion of the dried solid and the aqueous solution of Agaricus.

As Example 2, a squid-derived DHA-binding phospholipid was used as a raw material for liposome 2, agarix (manufactured by Health Science Co., Ltd., AICPLUS) was used as functional substance 3, and a liposome preparation 1 containing a functional substance was prepared. .
Agaricus was encapsulated in the liposome by the squid-3 highly unsaturated fatty acid binding phospholipid derived from squid.
First, a dried product of omega-3 highly unsaturated fatty acid-binding phospholipid was obtained by the same procedure as in Example 1.
Next, 0.5 g of Agaricus extract lyophilized powder was dissolved in 1000 cm ³ of pure water, 0.2 g of the dried product was further added, and the mixture was stirred with a vortex mixer for 20 minutes to form liposomes.
Next, it was passed through a membrane filter having a pore diameter of 0.4 μm 20 times, sizing and sterilization were performed, and a liposome preparation 1 containing the agaricus of Example 2 was prepared. In a liposomal formulation 1 containing the Agaricus of Example 2, the emulsion 1 cm ³ per DHA (omega-3) phospholipid content is 0.2 mg / cm ^3, Agaricus content per emulsion 1 cm ³ Was 0.5 mg. Here, when the liposome is charged and stabilized, phosphatidylserine (PS) and cholesterol may be appropriately added at the time of preparing the dried product.

Next, a comparative example will be described.
(Comparative Example 1)
Omega-3 highly unsaturated fatty acid-binding phospholipid derived from squid of Comparative Example 1 was prepared in the same manner as in Example 2 except that Agaricus was not blended. In the liposome preparation 1 of Comparative Example 1, the content of omega-3 highly unsaturated fatty acid-binding phospholipid mainly composed of DHA per 1 cm ³ of the emulsion is 0.2 mg / cm ³ .

(Comparative Example 2)
Agaricus alone was designated as Comparative Example 2.

Next, the effect of each composition prepared in Examples 1 and 2 and Comparative Examples 1 and 2 will be described.
Each composition was mixed with water to allow mice (BALB / c) to freely ingest it as a drink, and the effect on cancer cells (SP2tumors) inoculated into the mice was examined. The beverage was given every day from the seventh day after cancer cell inoculation.
Here, the mouse used for the test was a BALB / c male (nu / nu), admitted to the room at 5 weeks of age, and started the test at 6 weeks of age. For cancer cells SP2, 300,000 cells of each head were subcutaneously administered to the right armpit of 7 mice (number of samples n = 7). The mice were bred with a diet CL2 made by CLEA Japan. The concentration of each composition prepared in Examples 1 and 2 and Comparative Examples 1 and 2 to water was 0.4 mg / cm ³ .

First, comparison between Example 1 and Comparative Examples 1 and 2 will be described.
FIG. 2 shows the size of cancer cells inoculated in mice when water containing the compositions of Example 1 and Comparative Examples 1 and 2 was ingested freely. In FIG. 2, the horizontal axis indicates the number of days after cancer cell inoculation, and the vertical axis indicates the size (mm ³ ) of cancer cells. The figure also shows the data of mice that freely ingested water without any of the above-mentioned compositions for comparison and control with respect to Example 1 and Comparative Examples 1 and 2 (the absence of FIG. 1). See Administration).
As is clear from FIG. 2, the amount of cancer cells on the 21st day was 2 mm ³ , 4 mm ³ , 3.5 mm ³ and 7 mm ^{3 in} Example 1, Comparative Example 1, Comparative Example 2 and no administration, respectively. Thus, in the case of Example 1, only about 30% grew as compared with the case of no administration. From this, in the case of Example 1, the effect of suppressing the proliferation of cancer cells was remarkably recognized.

FIG. 3 is a graph showing the weight% of cancer cells on the 21st day relative to the body weight in Example 1 and Comparative Examples 1 and 2. In the figure, the vertical axis represents the weight% of cancer cells.
As is clear from FIG. 3, the weight percentages of cancer cells were 8% (about 24% without administration), 20%, 17 in Example 1, Comparative Example 1, Comparative Example 2, and no administration, respectively. In the case of the composition of Example 1, the weight% of cancer cells was about 24% without administration, and the effect of suppressing the growth of cancer cells was remarkably recognized. .

Next, comparison between Example 2 and Comparative Examples 1 and 2 will be described.
FIG. 4 is a graph showing the weight of cancer cells inoculated into mice when water containing the compositions of Example 2 and Comparative Examples 1 and 2 was freely taken. In the figure, the horizontal axis indicates the number of days after cancer cell inoculation, and the vertical axis indicates the weight (g) of cancer cells. The figure also shows the data of mice that freely ingested water without any of the above-mentioned compositions for comparison and control with respect to Example 2 and Comparative Examples 1 and 2 (FIG. 4). See Administration).
The amount of cancer cells on the 19th day was 20 g without administration, 15 g with liposomes only (Comparative Example 1), 3 g with Agaricus alone (Comparative Example 2), and 1 g in Example (5% with no administration), which has an inhibitory effect. Admitted.
As is clear from FIG. 4, in the mice that freely ingested water containing the liposome preparation 1 encapsulating Agaricus of Example 2, growth of cancer cells was gradually observed from the 19th day, and 27 g on the 35th day. But she was alive.

  Mice that freely ingested water containing squid-derived DHA (omega-3) phospholipid liposomes of Comparative Example 1 showed growth of cancer cells from the 12th day and died on the 19th day. The weight of the cancer cell was 30 g.

  The mice that freely ingested water containing agaricus of Comparative Example 2 gradually grew cancer cells from the 13th day and reached 40 g on the 35th day, but survived.

  On the other hand, in the case of no administration where no composition was administered, the growth of cancer cells was observed from the 12th day, and it died on the 19th day, and the weight of the cancer cells at that time was 38 g.

  According to the above Example 2 and Comparative Example, the growth of cancer cells is slowed in the order of Comparative Example 2 and Example 2 in the order of Comparative Example 2 and Example 2 compared to no administration and Comparative Example 1 that died on the 19th day. A cell growth inhibitory effect was observed. Furthermore, in the case of the liposome preparation 1 encapsulating agaricus of Example 2, a cancer cell growth inhibitory effect was further observed as compared with the case of comparatively administering Agarix alone. Moreover, in the case of the composition which consists only of the squid-derived DHA (omega-3) coupling | bonding phospholipid liposome of the comparative example 1, it turned out that the growth of a cancer cell is slow compared with the case where it does not administer.

As Example 3, a liposome preparation 1 containing a functional substance was prepared in the same manner as in Example 2 except that Coenzyme Q10 (manufactured by Nisshin Pharma) was used as the functional substance 3.
A total of 25 mg of a drink (100 cm ³ ) in which the functional material of Example 3 was dispersed was given to ³ healthy men.
As a comparative example, Neuquinone 10 mg tablets (Coenzyme Q10 preparation manufactured by Eisai Co., Ltd.) 10 tablets were orally administered once to 3 healthy persons. In this case, the dose of coenzyme Q10 is 100 mg. Blood was collected from both groups over time, and the coenzyme Q10 concentration in the plasma injection was measured. The time course curves of coenzyme Q10 concentration in plasma were almost the same in Example 3 group and Comparative group. In both groups, the maximum plasma concentration (0.55-0.70 μg / cm ³ ) was reached 6 hours after administration, and then gradually decreased.
As described above, the beverage containing the functional material 1 in which the coenzyme Q10 of Example 3 is encapsulated in useful phospholipid is efficiently incorporated into the body in an amount of 1/4 of the commercially available coenzyme Q10 preparation (Neuquinone). The plasma concentration of coenzyme Q10 could be increased.

  The functional material 1 containing the useful phospholipid of Example 4 was prepared in the same manner as in Example 2 except that the scallop-derived phospholipid described later was used.

The scallop-derived phospholipid was prepared as follows.
A useful phospholipid composition of Example 4 was produced using scallopuro as a starting material. The starting material, scallop, weighs 1000 kg and has been drained for a while but not particularly dry (hereinafter referred to as the wet standard). The breakdown is a solid content of 23% by weight and a water content of 770 kg. The protein in this solid content is about 13.5% in the case of scallops.
First, the starting material was continuously added, and the first cooking step and the second solid-liquid separation step were continuously performed. Specifically, 2000 liters of water was added to the starting material 1 and heated and boiled in a steam jacket heating type continuous steaming tube at 95 to 100 ° C. for 20 minutes.

  Subsequently, as a second solid-liquid separation step, it was passed through a continuous centrifugal separator and rotated at 2000 G to obtain a solid and a liquid phase. This liquid phase was recovered as waste. The weight of the solid obtained in this step was 470 kg, and the water content was 61.7% by weight as measured by Karl Fischer.

  As an organic solvent extraction step, 100 kg (dry solid content: about 38 kg) of the above-mentioned solid matter is filled into a stainless steel cylindrical extraction device (diameter 0.5 m, height 1.5 m, capacity 200 liters), 95 Extraction was performed by passing 300 liters of% ethanol at a flow rate of 100 liters / hour. Finally, the residual liquid phase was extruded with air, and this was added to the organic solvent extract to obtain about 400 liters of the organic solvent extract. The solid residue of the extraction residue obtained at this time was 35 kg.

As a fourth step, about 400 liters of the organic solvent extract was distilled under reduced pressure at 50 ° C. and 650 mmHg (about 8.7 × 10 ⁴ Pa) to remove and recover the organic solvent. The extract obtained here was a brown viscous liquid, and its weight was 15.5 kg.

  As a fifth step, the extract was passed through a stainless steel chromatographic column having a diameter of 50 cm and a height of 1.5 m. The chromatographic column is packed with silica gel. Silica gel (Hishigel, manufactured by Dokai Chemical Co., Ltd.) having a particle size of 250 to 500 μm was used. Separation was developed with 95 wt% ethanol. Among the effluent liquid phase, the dark black-brown initial fraction was separated and discarded, and then the effluent liquid phase which became light brown was collected as the target fraction.

  Next, as a sixth step, ethanol was distilled off from the purified solution under the same conditions as in the fourth step, to obtain 7.8 kg of an oil phase as a useful phospholipid composition. This useful phospholipid composition had a black-brown appearance and an oily appearance.

  In the same manner as in Examples 1 and 2, a drinking water addition test was conducted on mice. As a result, the amount of cancer cells on the 19th day was 1.2 g, 30 g, 4 g, and 39 g in Example 4, Comparative Example 1, Comparative Example 2, and no administration, respectively. In the case of Example 4, the amount of cancer cells was as small as 3% with no administration, indicating a high cancer cell suppression effect.

  From the above Examples 1 to 4 and Comparative Examples 1 and 2, it was found that the functional material containing the useful phospholipid composition of the present invention exhibits a high cancer cell suppression effect.

  The present invention is not limited to the above-described embodiments, and various modifications are possible within the scope of the invention described in the claims, and it goes without saying that these are also included in the scope of the present invention. . For example, the pH in the production process of the liposome preparation encapsulating the functional substance, the chromatographic column in the purification process by the chromatographic method, and the like can be designed as appropriate, and the seafood parts are derived from the scallops and squids in the above examples. Needless to say, it is not limited to.

It is a figure which shows typically the structure of another functional material of this invention. It is a figure which shows the magnitude | size of the cancer cell inoculated to the mouse | mouth when the water containing the composition of Example 1 and Comparative Examples 1 and 2 was ingested freely. In Example 1 and Comparative Examples 1 and 2, it is the figure which showed weight% with respect to the body weight of the 21st day cancer cell. It is a figure which shows the weight of the cancer cell inoculated to the mouse | mouth when the water containing the composition of Example 2 and Comparative Examples 1 and 2 was ingested freely.

Explanation of symbols

1: Liposome preparation containing a functional substance (liposome preparation)
2: Liposomes composed of useful phospholipids 3: Functional substances

Claims (11)

  A functional material containing a useful phospholipid composition, comprising a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid and a functional substance as active ingredients. A liposome composed of a useful phospholipid composition containing omega-3 highly unsaturated fatty acid-binding phospholipid, and a functional substance,
A functional material containing a useful phospholipid composition, wherein the functional substance is encapsulated in the liposome.   The omega-3 polyunsaturated fatty acid-binding phospholipid is 10% by weight or more, preferably 20% by weight or more, of DFA (docosahexaenoic acid) and / or EPA (eicosapentaenoic acid). A functional material comprising the useful phospholipid composition according to claim 1, wherein the functional material comprises the useful phospholipid composition according to claim 1.   The useful phospholipid according to claim 3, wherein the omega-3 highly unsaturated fatty acid-binding phospholipid is a useful phospholipid composition in which the content of omega-3 highly unsaturated fatty acid is increased by transesterification. Functional material containing the composition.   The functional material containing the useful phospholipid composition according to claim 1, wherein the functional substance is a functional food material.   The functional material containing the useful phospholipid composition according to claim 1, wherein the functional substance is a pharmaceutical material.   The functional material containing the useful phospholipid composition according to claim 1, wherein the functional substance is Agaricus.   The functional material containing the useful phospholipid composition according to claim 1, wherein the functional substance is coenzyme Q10.   The omega-3 polyunsaturated fatty acid-binding phospholipid is derived from an aquatic product, and the aquatic product is any of fish eggs, aquatic animal gonads, squid, scallops, starfish, seaweed, and microorganisms. A functional material comprising the useful phospholipid composition according to claim 1 or 2.   A functional food comprising a functional material containing the useful phospholipid composition according to claim 1. The functional food according to claim 10, wherein the functional food is a beverage.